Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescein Sodium Dosage for Gastric Intestinal Metaplasia Detection
NCT02534818Phase 4Unknown
- Sponsor
- Shandong University
- Start
- Jun 2015
- Primary completion
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fluorescein in gastric intestinal metaplasia (IM) (2 arms), sponsored by Shandong University. Primary endpoints: Difference of the detection rate of gastric intestinal metaplasia between two fluosecein sodium dosage in a per-pateint analysis at 6 months and Difference of the detection rate of gastric intestinal metaplasia between two dosage fluosecein sodium in a per-biopsy analysis at 6 months. Status: unknown.
02
Drugs
fluorescein
03
Conditions
gastric intestinal metaplasia (IM)
Beyond the preview
Go deeper on NCT02534818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534818.